It was determined to have both good in vitro cellular potency (IC50 for PARP-1 inhibition of 6 nM) and in vivo efficacy because it led to 80% tumor inhibition when fed in combination with temozolomide to mice [22]. This evidence concerns the gene PARP1 and neoplasm.